Bupropion for Desire After Cancer
Intimate HealthArticleNeither tested dose showed benefit over placebo.
In this article
The comparison
NRG-CC004 randomized 230 postmenopausal breast or gynecologic cancer survivors to 150mg or 300mg extended-release bupropion, or placebo. At week nine, after eight weeks at target dose, changes on the desire scale (1.2–6) differed from placebo by +0.02 points (95% confidence interval −0.36 to 0.39) and −0.02 (−0.40 to 0.36), respectively. Neither comparison showed benefit.1
The boundaries
Active depression/anxiety and tamoxifen use were excluded. At week nine, 195 completed questionnaires, 189 within the assessment window. Longitudinal models assumed outcomes were missing at random. This does not establish equivalence or test depression treatment.1
NCI and the Breast Cancer Research Foundation funded the trial; authors disclosed industry relationships.1
The prescription discussion
US Wellbutrin XL is approved for major depression and seasonal affective disorder, not low desire. Its label warns that inhibiting CYP2D6 could theoretically reduce tamoxifen’s effectiveness. Have the oncology team and prescriber review the combination; do not change either medicine yourself.2
The label contraindicates use with seizure disorders, current or past bulimia/anorexia, abrupt withdrawal from alcohol, benzodiazepines, barbiturates or antiepileptic medicines, and specified MAOI combinations. Seizure risk rises with dose; blood pressure needs monitoring. Report new suicidal thoughts or unusual behavioral changes immediately.2
The National Cancer Institute3 advises addressing pain, fatigue, sleep problems and other treatment effects that can affect sexual health. Vaginal discomfort and low desire may need different assessments. Ask which symptoms need treatment, whether a medicine contributes, and whether a sexual-health specialist or counselor could help. Cancer type and treatment matter when choosing vaginal medicines.3
Our antidepressant sexual-effects article discusses a different treatment question. Down There, Decoded examines medication timing and other influences on desire in “What Gets in the Way.” See the book.
Educational information, not personal medical advice. Discuss prescription changes with your clinician.
Girl Playbook sells this book. It provides education and worksheets, not individualized medical care.
Sources
The research behind this article, in the order it’s cited. How we source our articles.
- Journal of Clinical Oncology, 2022NRG-CC004 bupropion trial (opens in a new tab)abc
- DailyMed, 2026Wellbutrin XL prescribing information (opens in a new tab)ab
- National Cancer Institute, 2022Sexual health issues in women with cancer (opens in a new tab)ab
Spotted something out of date? Tell us and we’ll check it.
